• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Unity Biotechnology Inc.

    4/3/25 4:16:03 PM ET
    $UBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UBX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001727640
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    UNITY BIOTECHNOLOGY, INC.
    SEC File Number
    001-38470
    Address of Issuer
    285 East Grand Ave.
    South San Francisco
    CALIFORNIA
    94080
    Phone
    (650)-416-1192
    Name of Person for Whose Account the Securities are To Be Sold
    Sullivan Lynne Marie
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Muriel Siebert & Co., LLC
    18045 Oak Street
    Omaha � NE � 68130
    2186722422.429890504/02/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock03/28/2025Restricted Stock Units granted in 2025 under the Issuer's 2018 Incentive Award PlanUNITY Biotechnology, Inc.Checkbox not checked2186703/28/2025N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Lynne Marie Sullivan
    C/O UNITY BIOTECHNOLOGY, INC.
    285 East Grand Avenue
    South San Francisco � CA � 94080
    Restricted Stock Units granted in 2022 under the Issuer's 2018 Incentive Award Plan02/04/2025153341.19

    144: Remarks and Signature

    Remarks
    1. Share number reflects post-split units after 1-for-10 reverse stock split as of 10/19/22.
    Date of Notice
    04/03/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Alexander Nguyen as attorney-in-fact for Lynne Sullivan pursuant to Power of Attorney

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $UBX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UBX

    DatePrice TargetRatingAnalyst
    5/27/2025$2.00Buy → Neutral
    H.C. Wainwright
    5/16/2025$6.00 → $1.00Outperform → Neutral
    Mizuho
    8/22/2024$8.00Buy
    Rodman & Renshaw
    11/16/2023$2.00 → $4.00Neutral → Outperform
    Wedbush
    1/4/2022$4.00Neutral → Buy
    Roth Capital
    1/4/2022Neutral → Buy
    ROTH Capital
    11/10/2021$5.00 → $7.00Neutral → Buy
    Mizuho
    6/28/2021Sell → Buy
    Citigroup
    More analyst ratings